121 related articles for article (PubMed ID: 23331234)
1. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
[TBL] [Abstract][Full Text] [Related]
2. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
3. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.
Hwang TJ; Franklin JM; Kesselheim AS
Clin Pharmacol Ther; 2017 Aug; 102(2):290-296. PubMed ID: 28390139
[TBL] [Abstract][Full Text] [Related]
4. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
McGuire DK; Marx N; Johansen OE; Inzucchi SE; Rosenstock J; George JT
Diabetes Obes Metab; 2019 May; 21(5):1073-1078. PubMed ID: 30690856
[TBL] [Abstract][Full Text] [Related]
5. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS
Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161
[TBL] [Abstract][Full Text] [Related]
6. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.
Goyat R; Rai P; Chang J; Ponte CD; Tan X
Clin Drug Investig; 2018 Jun; 38(6):491-501. PubMed ID: 29564723
[TBL] [Abstract][Full Text] [Related]
8. Model-based benefit-risk assessment: can Archimedes help?
Krishna R
Clin Pharmacol Ther; 2009 Mar; 85(3):239-40. PubMed ID: 19223878
[TBL] [Abstract][Full Text] [Related]
9. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
10. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
Panicker GK; Karnad DR; Salvi V; Kothari S
J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
[TBL] [Abstract][Full Text] [Related]
11. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
Malesker MA
Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
[TBL] [Abstract][Full Text] [Related]
12. Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs.
Marcinak JF; Viswanathan P; Arora V; Roebel LE; Strack TR; Leifke E
Clin Pharmacol Ther; 2012 Mar; 91(3):514-20. PubMed ID: 22113235
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Viereck C; Boudes P
Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
[TBL] [Abstract][Full Text] [Related]
14. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
15. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on.
Mullard A
Nat Rev Drug Discov; 2018 Dec; 17(12):850-851. PubMed ID: 30443037
[No Abstract] [Full Text] [Related]
16. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
17. Should recent experiences with CVOTs for oral hypoglycemic drugs allow us to rethink the regulatory paradigm?
Meyer RJ
Clin Pharmacol Ther; 2015 Nov; 98(5):467-9. PubMed ID: 26234476
[TBL] [Abstract][Full Text] [Related]
18. A review of cardiovascular outcome trials in type 2 diabetes.
Cypryk K; Małecki P
Endokrynol Pol; 2018; 69(4):. PubMed ID: 30209802
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
20. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
[Next] [New Search]
